CagriSema — Novo Nordisk's Next Move

Medical Disclaimer: ShedPilot is a nutrition and wellness app, not a medical provider. This content is for educational purposes only. Always consult your healthcare provider before starting any medication or supplement.

What Is CagriSema?

CagriSema is a fixed-dose combination of cagrilintide and semaglutide, both developed by Novo Nordisk. Cagrilintide is a long-acting analogue of amylin — a hormone co-secreted with insulin from pancreatic beta cells that plays a role in satiety, gastric emptying, and glucose regulation. By combining it with semaglutide, Novo Nordisk targets two complementary hormonal pathways simultaneously.

~25%

Average weight loss in early CagriSema trials

Once/wk

Dosing — combined into a single weekly injection

Complementary hormone pathways targeted

The Role of Amylin

Amylin works alongside insulin to regulate blood sugar and appetite. It slows gastric emptying, suppresses glucagon, and signals satiety to the brain through pathways partially distinct from GLP-1. A synthetic amylin analogue called pramlintide was previously approved (as Symlin) for use with insulin in diabetes, but its short half-life required multiple daily injections. Cagrilintide is engineered for once-weekly dosing, making it practical as part of a combination product.

Early Trial Results

Phase 2 results from the COMBINE 1 trial showed CagriSema producing approximately 15% weight reduction compared to approximately 10% for semaglutide alone at the doses studied. More extensive trials have shown weight loss approaching 25% at highest doses, positioning CagriSema as Novo Nordisk's answer to tirzepatide's efficacy advantage over Wegovy.

Current Status (Updated August 2026)

CagriSema has completed its pivotal Phase 3 program (REDEFINE trials). The REDEFINE-1 trial — the largest Phase 3 obesity trial — reported 22.7% average weight loss at 68 weeks with the highest dose combination. Novo Nordisk filed a New Drug Application (NDA) with the FDA on December 18, 2025. An FDA decision is expected in Q4 2026. CagriSema is not yet approved and is not available outside clinical trials. Expected launch price has been estimated at $1,400–$1,600 per month, though final pricing has not been announced.

CagriSema represents Novo Nordisk's strategy for competing with tirzepatide's efficacy advantage — targeting a second hormonal pathway (amylin) rather than a second incretin (GIP) as Lilly did with tirzepatide.

October 2026 Update: PDUFA Date & FDA Review Status

NDA Filed December 2025 — FDA Decision Expected December 31, 2026: Novo Nordisk filed the NDA for CagriSema on December 18, 2025. The FDA has accepted the filing and a regulatory decision is expected by Q4 2026 — with the target action date understood to be on or before December 31, 2026. CagriSema would be the first GLP-1 + amylin combination approved for obesity. No public PDUFA date has been officially disclosed by FDA, but Novo Nordisk has guided investors to a Q4 2026 decision window. Watch for an FDA action announcement in the coming weeks. (Updated October 23, 2026)

September 2026 Update: FDA Decision Expected This Quarter

PDUFA Window — September/Q4 2026: CagriSema's FDA review is now in its final quarter. Novo Nordisk filed its NDA in December 2025, and the PDUFA decision date falls in Q4 2026 — making October–December 2026 the critical window. If approved, CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg, once weekly injection) would become the highest-efficacy obesity drug ever FDA-approved, surpassing Wegovy's ~15% average weight loss with the REDEFINE-1 trial result of 22.7% at 68 weeks. Analysts are closely watching whether FDA requests an advisory committee meeting or issues any information requests that could push the timeline. No such delays have been publicly reported as of September 2026. A positive approval would represent Novo Nordisk's most significant regulatory milestone since Wegovy's 2021 approval and would directly challenge tirzepatide's efficacy position in the market.

October 2026 Update: EASD 2026 — fMRI Brain Data & FDA Decision Imminent

EASD 2026 Milan (September 28 – October 2, 2026): Novo Nordisk presented new CagriSema data at EASD 2026 showing how the drug affects brain responses to food cues using fMRI — providing the first mechanistic window into how the GLP-1 + amylin combination regulates appetite at the neurological level. Additional EASD data covered CagriSema's effects on body composition (organ-level fat and lean mass), bone remodelling mechanisms, and CagriSema outcomes in people with type 2 diabetes. These data strengthen the NDA package as the FDA decision window approaches. The FDA PDUFA date for CagriSema remains in Q4 2026. No advisory committee meeting has been convened, and no information requests from FDA have been publicly disclosed — suggesting the review is proceeding on track. A decision is expected before year-end 2026. Source: Novo Nordisk EASD 2026 press release; BioSpace, September 16, 2026.

November 2026 Update: ObesityWeek 2026 Data & FDA Decision Imminent

ObesityWeek 2026 — Washington D.C. (November 14–17, 2026): Novo Nordisk announced it will present 26 abstracts at ObesityWeek 2026, including new post-hoc analyses from the pivotal REDEFINE 1 trial (investigating changes in weight-related quality of life), and primary results from REDEFINE 9, which tested lower doses of CagriSema. Separately, the confirmed FDA PDUFA target date for CagriSema is December 2026 — with market intelligence sources tracking a decision on or before December 31, 2026. No advisory committee meeting has been convened and no FDA information requests have been publicly disclosed, suggesting the review is proceeding on schedule. If approved this month or in December, CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg, once-weekly injection) would become the highest-efficacy obesity drug ever FDA-approved. Source: Novo Nordisk / pdufa.bio, November 2026. (Updated November 2, 2026)

CagriSema (Cagrilintide + Semaglutide)